Cited by 2,323COVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchRespiratory viral infections research

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19

Open access

Hammond, Jennifer, Leister-Tebbe, Heidi, Gardner, Annie, Abreu, Paula, Bao, Weihang, Wisemandle, Wayne, Baniecki, MaryLynn, Hendrick, Victoria M., Damle, Bharat, Simón-Campos, Abraham, Pypstra, Rienk, Rusnak, James M.·2022·New England Journal of Medicine

DOI 10.1056/nejmoa2118542PMC PMC8908851

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUNDNirmatrelvir is an orally administered severe acute respiratory syndrome coronavirus 2 main protease (M pro ) inhibitor with potent pan-human-coronavirus activity in vitro. METHODSWe conducted a phase 2-3 double-blind, randomized, controlled trial in which symptomatic, unvaccinated, nonhospitalized adults at high risk for progression to severe coronavirus disease 2019 (Covid-19) were assigned in a 1:1 ratio to receive either 300 mg of nirmatrelvir plus 100 mg of ritonavir (a pharmacokinetic enhancer) or placebo every 12 hours for 5 days.Covid-19-related hospitalization or death from any cause through day 28, viral load, and safety were evaluated. RESULTSA total of 2246 patients underwent randomization; 1120 patients received nirmatrelvir plus ritonavir (nirmatrelvir group) and 1126 received placebo (placebo group).In the planned interim analysis of patients treated within 3 days after symptom onset (modified intention-to treat population, comprising 774 of the 1361 patients in the full analysis population), the incidence of Covid-19-related hospitalization or death by day 28 was lower in the nirmatrelvir group than in the placebo group by 6.32 percentage points (95% confidence interval [CI], -9.04 to -3.59; P<0.001; relative risk reduction, 89.1%); the incidence was 0.77% (3 of 389 patients) in the nirmatrelvir group, with 0 deaths, as compared with 7.01% (27 of 385 patients) in the placebo group, with 7 deaths.Efficacy was maintained in the final analysis involving the 1379 patients in the modified intention-to-treat population, with a difference of -5.81 percentage points (95% CI, -7.78 to -3.84; P<0.001; relative risk reduction, 88.9%).All 13 deaths occurred in the placebo group.The viral load was lower with nirmatrelvir plus ritonavir than with placebo at day 5 of treatment, with an adjusted mean difference of -0.868 log 10 copies per milliliter when treatment was initiated within 3 days after the onset of symptoms.The incidence of adverse events that emerged during the treatment period was similar in the two groups (any adverse event, 22.6% with nirmatrelvir plus ritonavir vs. 23.9% with placebo; serious adverse events, 1.6% vs. 6.6%; and adverse events leading to discontinuation of the drugs or placebo, 2.1% vs. 4.2%).Dysgeusia (5.6% vs. 0.3%) and diarrhea (3.1% vs. 1.6%) occurred more frequently with nirmatrelvir plus ritonavir than with placebo. CONCLUSIONSTreatment of symptomatic Covid-19 with nirmatrelvir plus ritonavir resulted in a risk of progression to severe Covid-19 that was 89% lower than the risk with placebo, without evident safety concerns.(Supported by Pfizer; ClinicalTrials.govnumber, NCT04960202.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa2118542

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention
Wu, Z., & McGoogan, J. M. (2020) · JAMA · doi:10.1001/jama.2020.2648 · Cited by 17,016
Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019
Roth, G. A., Mensah, G. A., Johnson, C. O., Addolorato, G., Ammirati, E., Baddour, L. M., Barengo, N. C., Beaton, A. Z., Benjamin, E. J., Benziger, C. P., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.11.010 · Cited by 11,449
Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants.
(2016) · The Lancet · doi:10.1016/s0140-6736(16)30054-x · Cited by 5,212
SARS-CoV-2 variants, spike mutations and immune escape
Harvey, W. T., Carabelli, A. M., Jackson, B., Gupta, R. K., Thomson, E. C., Harrison, E. M., Ludden, C., Reeve, R., Rambaut, A., COVID-19 Genomics UK (COG-UK) Consortium, et al. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00573-0 · Cited by 3,528
Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study
Docherty, A. B., Harrison, E. M., Green, C. A., Hardwick, H. E., Pius, R., Norman, L., Holden, K. A., Read, J. M., Dondelinger, F., Carson, G., et al. (2020) · BMJ · doi:10.1136/bmj.m1985 · Cited by 3,481
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis
Zheng, Z., Peng, F., Xu, B., Zhao, J., Liu, H., Peng, J., Li, Q., Jiang, C., Zhou, Y., Liu, S., et al. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.04.021 · Cited by 2,074
An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19
Owen, D. R., Allerton, C. M. N., Anderson, A. S., Aschenbrenner, L., Avery, M., Berritt, S., Boras, B., Cardin, R. D., Carlo, A., Coffman, K. J., et al. (2021) · Science · doi:10.1126/science.abl4784 · Cited by 2,033

Flagged first, then by citations

Show all 21 references

Sorted by citations

Items 801–900 of 1,002

Clinical Features of COVID-19 in Pediatric Rheumatic Diseases: 2020–2022 Survey of the Pediatric Rheumatology Association of Japan
Wakiguchi, H., Kaneko, U., Sato, S., Imagawa, T., Narazaki, H., & Miyamae, T. (2023) · Viruses · doi:10.3390/v15051205 · Cited by 9
Pharmacokinetics, safety, and tolerability of inhaled remdesivir in healthy participants
Humeniuk, R., Juneja, K., Chen, S., Ellis, S., Anoshchenko, O., Xiao, D., Share, A., Johnston, M., Davies, S., DeZure, A. D., et al. (2023) · Clinical and Translational Science · doi:10.1111/cts.13627 · Cited by 9
Nirmatrelvir/Ritonavir Use and Hospitalizations or Death in a Previously Uninfected Nonhospitalized High-Risk Population With COVID-19: A Matched Cohort Study
Butt, A. A., Peng, Y., Shaikh, O. S., Talisa, V. B., Omer, S. B., & Mayr, F. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad393 · Cited by 9
Quality of reporting of adverse events in clinical trials of covid-19 drugs: systematic review
Madi, K., Flumian, C., Olivier, P., Sommet, A., & Montastruc, F. (2023) · BMJ Medicine · doi:10.1136/bmjmed-2022-000352 · Cited by 10
Dosing recommendation of nirmatrelvir/ritonavir using an integrated population pharmacokinetic analysis
Chan, P. L. S., Singh, R. S. P., Cox, D. S., Shi, H., Damle, B. D., & Nicholas, T. (2023) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.13039 · Cited by 9
Self-citation
Cost-effectiveness of therapeutics for COVID-19 patients: a rapid review and economic analysis
Metry, A., Pandor, A., Ren, S., Shippam, A., Clowes, M., Dark, P. M., McMullan, R., & Stevenson, M. (2023) · Health Technology Assessment · doi:10.3310/nafw3527 · Cited by 9
SARS-CoV-2: The Virus, Its Biology and COVID-19 Disease-Counteracting Possibilities
Marschalek, R. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2810273 · Cited by 9
Metabolic and toxicological considerations regarding CGRP mAbs and CGRP antagonists to treat migraine in COVID-19 patients: a narrative review
Takizawa, T., Ihara, K., Uno, S., Ohtani, S., Watanabe, N., Imai, N., Nakahara, J., Hori, S., García‐Azorín, D., & Martelletti, P. (2023) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2023.2280221 · Cited by 9
Evaluation of oral small molecule drugs for the treatment of COVID-19 patients: a systematic review and network meta-analysis
Chen, Z., & Tian, F. (2023) · Annals of Medicine · doi:10.1080/07853890.2023.2274511 · Cited by 9
Effectiveness of Molnupiravir Treatment in Patients with COVID-19 in Korea: A Propensity Score Matched Study
Park, H. R., Yoo, M., Kim, J.-M., Bae, S. J., Lee, H., & Kim, J. (2023) · Infection and Chemotherapy · doi:10.3947/ic.2023.0087 · Cited by 9
Clinical development of antivirals against SARS-CoV-2 and its variants
Lan, Q., Yan, Y., Zhang, G., Xia, S., Zhou, J., Lu, L., & Jiang, S. (2023) · Current Research in Microbial Sciences · doi:10.1016/j.crmicr.2023.100208 · Cited by 9
Intravenous immunoglobulin as a potential treatment for long COVID
McCarthy, M. W. (2023) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2023.2296569 · Cited by 9
Existence of Quantum Pharmacology in Sartans: Evidence in Isolated Rabbit Iliac Arteries
Gadanec, L. K., Swiderski, J., Apostolopoulos, V., Kelaidonis, K., Vidali, V. P., Canko, A., Moore, G. J., Matsoukas, J., & Zulli, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417559 · Cited by 11
Effectiveness and safety of azvudine in older adults with mild and moderate COVID-19: a retrospective observational study
Zhou, Z., Zheng, H., Xiao, G., Xie, X., Rang, J., & Peng, D. (2024) · BMC Infectious Diseases · doi:10.1186/s12879-023-08944-z · Cited by 9
Overview of COVID-19 Infection, Treatment, and Prevention in Children
Kao, C. M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13020424 · Cited by 9
Comparison of azvudine, molnupiravir, and nirmatrelvir/ritonavir in adult patients with mild-to-moderate COVID-19: a retrospective cohort study
Chen, M., Jiang, D., Rang, J., Zhuo, H.-B., & Zhou, Z. (2024) · Scientific Reports · doi:10.1038/s41598-024-53862-y · Cited by 9
A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2023
Kayki‐Mutlu, G., Aksoyalp, Z. Ş., Wojnowski, L., & Michel, M. C. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03063-1 · Cited by 9
Nirmatrelvir/ritonavir and remdesivir against symptomatic treatment in high-risk COVID-19 outpatients to prevent hospitalization or death during the Omicron era: a propensity score-matched study
Rajme‐López, S., Martínez-Guerra, B. A., Román-Montes, C. M., Tamez-Torres, K. M., Tello-Mercado, A. C., Tepo-Ponce, K. M., Segura-Ortíz, Z., López-Aguirre, A., Gutiérrez-Mazariegos, O. D. R., Lazcano-Delgadillo, O., et al. (2024) · Therapeutic Advances in Infectious Disease · doi:10.1177/20499361241236582 · Cited by 9
Economic Evaluation of Nirmatrelvir/Ritonavir Among Adults Against Hospitalization During the Omicron Dominated Period in Malaysia: A Real-World Evidence Perspective
Low, E. V., Teh, H. S., Hing, N. Y. L., Chidambaram, S. K., Pathmanathan, M. D., Kim, W. R., Lee, W. J., Teh, Z. W., Appannan, M. R., Zin, S. M., et al. (2024) · Drugs - Real World Outcomes · doi:10.1007/s40801-024-00427-0 · Cited by 9
Combination of spironolactone and DPP-4 inhibitors for treatment of SARS-CoV-2 infection: a literature review
Asadipooya, K., Asadipooya, A., & Adatorwovor, R. (2024) · Archives of Virology · doi:10.1007/s00705-024-06043-1 · Cited by 9
Olgotrelvir as a Single-Agent Treatment of Nonhospitalized Patients with Covid-19
Jiang, R., Han, B., Xu, W., Zhang, X., Peng, C., Dang, Q., Sun, W., Lin, L., Lin, Y., Fan, L., et al. (2024) · NEJM Evidence · doi:10.1056/evidoa2400026 · Cited by 9
Managing and treating COVID-19 in patients with hematological malignancies: a narrative review and expert insights
Ng, H. J., Alata, M. K., Nguyen, Q. T., Vinh, P. H. D., Tan, J. Y., & Wong, C. L. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01381-5 · Cited by 9
Identifying Veterans Who Benefit From Nirmatrelvir-Ritonavir: A Target Trial Emulation
Yan, L., Bui, D. P., Li, Y., Rajeevan, N., Rowneki, M., Berry, K., Argraves, S., Huang, Y., Hynes, D. M., Cunningham, F. E., et al. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae202 · Cited by 9
Design, Synthesis, and Biological Evaluation of 1,2,4-Oxadiazole Derivatives Containing an Aryl Carboxylic Acid Moiety as Potent Sarbecovirus Papain-like Protease Inhibitors
Qin, B., Wu, C., Zhao, B., Li, G., Wang, B., Ou, M., Li, Z., Lang, X., Li, P., Liu, J., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00534 · Cited by 9
Covalent drug – An emerging framework for targeted drug development
Bhole, R. P., Joshi, G. O., Kapare, H. S., Chikhale, R. V., & Chaudhari, S. Y. (2024) · Results in Chemistry · doi:10.1016/j.rechem.2024.101615 · Cited by 10
Predicting Clinical Outcomes of SARS‐CoV‐2 Drug Efficacy with a High‐Throughput Human Airway Microphysiological System
Quezada, L. A. L., Medie, F. M., Luu, R. J., Gaibler, R. B., Gabriel, E. P., Rubio, L. D., Mulhern, T. J., Marr, E. E., Borenstein, J. T., Fisher, C. R., et al. (2024) · Advanced Biology · doi:10.1002/adbi.202300511 · Cited by 9
Computational Evidence for Bisartan Arginine Blockers as Next-Generation Pan-Antiviral Therapeutics Targeting SARS-CoV-2, Influenza, and Respiratory Syncytial Viruses
Ridgway, H. F., Apostolopoulos, V., Moore, G. J., Gadanec, L. K., Zulli, A., Swiderski, J., Tsiodras, S., Kelaidonis, K., Chasapis, C. T., & Matsoukas, J. (2024) · Viruses · doi:10.3390/v16111776 · Cited by 9
Using nirmatrelvir/ritonavir in patients with epilepsy: An update from the Israeli chapter of the International League Against Epilepsy
Noyman, I., Ekstein, D., Fahoum, F., Herskovitz, M., Linder, I., Zeev, B. B., & Eyal, S. (2022) · Epilepsia · doi:10.1111/epi.17212 · Cited by 9
The Role of Oral Antivirals for COVID-19 Treatment in Shaping the Pandemic Landscape
Anastassopoulou, C. G., Hatziantoniou, S., Boufidou, F., Patrinos, G. P., & Tsakris, A. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12030439 · Cited by 9
COVID-19-Current Therapeutical Approaches and Future Perspectives
Moisi, R. E., Nedea, M. I., Velescu, B. Ș., Udeanu, D. I., Sultana, C., Ruță, S. M., & Arsene, A. L. (2022) · Processes · doi:10.3390/pr10061053 · Cited by 9
Three more points about Paxlovid for covid-19
Phizackerley, D. (2022) · BMJ · doi:10.1136/bmj.o1397 · Cited by 9
Ultra-Long-Acting Antivirals as Chemical Vaccines to Prevent Viral Diseases
Soriano, V., Edagwa, B., de Mendoza, C., Barreiro, P., Corral, O. J., Treviño, A., & Gendelman, H. E. (2022) · Future Microbiology · doi:10.2217/fmb-2021-0254 · Cited by 9
Case report: Application of nirmatrelvir/ritonavir to treat COVID-19 in a severe aplastic anemia child after allogeneic hematopoietic stem cell transplantation
Huang, J., Yin, D., Qin, X., Yu, M., Jiang, B., Chen, J., Cao, Q., & Tang, Z. (2022) · Frontiers in Pediatrics · doi:10.3389/fped.2022.935118 · Cited by 9
Can nirmatrelvir/ritonavir treatment shorten the duration of COVID-19 isolation?
Kim, H., Yang, J., Ko, J., Lee, M., Lee, J., Park, S., Kim, J.-W., Shin, Y., Lee, J., Na, Y. J., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.988559 · Cited by 9
Monoclonal Antibodies and Antivirals against SARS-CoV-2 Reduce the Risk of Long COVID: A Retrospective Propensity Score-Matched Case–Control Study
Cimellaro, A., Addesi, D., Cavallo, M., Spagnolo, F., Suraci, E., Cordaro, R., Spinelli, I., Passafaro, F., Colosimo, M., Pintaudi, M., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10123135 · Cited by 9
Use of remdesivir for COVID-19 in patients with hematologic cancer
Martin‐Onraët, A., Barrientos-Flores, C. D. J., Vilar‐Compte, D., Pérez‐Jimenez, C., & Alatorre-Fernández, P. (2022) · Clinical and Experimental Medicine · doi:10.1007/s10238-022-00964-4 · Cited by 9
Liver tests abnormalities with licensed antiviral drugs for COVID-19: a narrative review
Casalini, G., Giacomelli, A., & Antinori, S. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2160446 · Cited by 9
HIV and COVID-19 Disease
Venturas, J. P. (2023) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0042-1758852 · Cited by 9
Effectiveness of Favipiravir monotherapy in the treatment of COVID-19: real world data analysis from Thailand
Srisubat, A., Thanasitthichai, S., Kongsaengdao, S., Maneeton, N., Maneeton, B., & Akksilp, S. (2023) · The Lancet Regional Health - Southeast Asia · doi:10.1016/j.lansea.2023.100166 · Cited by 9
Discovery of Chalcone-Based Hybrid Structures as High Affinity and Site-Specific Inhibitors against SARS-CoV-2: A Comprehensive Structural Analysis Based on Various Host-Based and Viral Targets
Valipour, M., Giacomo, S. D., Sotto, A. D., & Irannejad, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108789 · Cited by 9
Nasal spray of an IgM‐like ACE2 fusion protein HH‐120 accelerates SARS‐CoV‐2 clearance: A single‐center propensity score‐matched cohort study
Song, R., Chen, X., Li, B., Zhang, H., Guo, X., Liu, Z., Zou, L., Xiao, L., Lei, C., Mao, F., et al. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28805 · Cited by 10
CROI 2025: Acute and Postacute COVID-19
Antar, A. A. R., & Peluso, M. J. (2025) · Topics in antiviral medicine · doi:10.68040/2025333.555568 · Cited by 9
Adaptative Strategy of Immunosuppressive Drugs Dosage Adjustments When Combined With Nirmatrelvir/Ritonavir in Solid Organ Transplant Recipients With COVID-19
Boland, L., Devresse, A., Monchaud, C., Briol, S., Belaiche, S., Giguet, B., Couzi, L., Thaunat, O., Esposito, L., Meszaros, M., et al. (2024) · Transplant International · doi:10.3389/ti.2024.12360 · Cited by 9
Characteristics and outcomes of patients with COVID-19 at high risk of disease progression receiving sotrovimab, oral antivirals or no treatment in England: a retrospective cohort study
Patel, V., Yarwood, M. J., Levick, B., Gibbons, D. C., Drysdale, M., Kerr, W. A., Watkins, J. D., Young, S., Pierce, B. F., Lloyd, E. J., et al. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2376144 · Cited by 9
Real-world Use of Nirmatrelvir-Ritonavir in COVID-19 Outpatients During the Emergence of Omicron Variants BA.2/BA2.12.1Preprint
Aggarwal, N. R., Molina, K. C., Beaty, L. E., Bennett, T. D., Carlson, N. E., & Ginde, A. A. (2022) · medRxiv · doi:10.1101/2022.09.12.22279866 · Cited by 9
Executive summary of the consensus statement of the group for the study of infection in transplantation and other immunocompromised host (GESITRA-IC) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) on the treatment of SARS-CoV-2 infection in solid organ transplant recipients
Herrera, S., Aguado, J. M., Candel, F. J., Cordero, E., Domínguez‐Gil, B., Fernández‐Ruiz, M., Arcos, I. L., Len, Ó., Marcos, M. Á., Múñez, E., et al. (2023) · Transplantation Reviews · doi:10.1016/j.trre.2023.100788 · Cited by 9
Biology Is Not Destiny
Horwitz, R. I., & Cullen, M. R. (2023) · Psychotherapy and Psychosomatics · doi:10.1159/000533449 · Cited by 9
Metformin on Time to Sustained Recovery in Adults with COVID-19: The ACTIV-6 Randomized Clinical Trial
Bramante, C. T., Stewart, T. G., Boulware, D. R., McCarthy, M. W., Gao, Y., Rothman, R. L., Mourad, A., Thicklin, F., Cohen, J. B., Garcia del Sol, I. T., et al. (2025) · doi:10.1101/2025.01.13.25320485 · Cited by 8
Metformin and Time to Sustained Recovery in Adults With COVID-19: The ACTIV-6 Randomized Clinical Trial
Bramante, C. T., Stewart, T. G., Boulware, D. R., McCarthy, M. W., Gao, Y., Rothman, R. L., Mourad, A., Thicklin, F., Cohen, J. B., Garcia del Sol, I. T., et al. (2025) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2025.2570 · Cited by 8
Pharmacovigilance of Drug–Drug Interactions with Nirmatrelvir/Ritonavir
Hendrick, V., Pohorylo, E., Merchant, L., Gerhart, J., Arham, I. N., Draica, F., Quercia, R., Ayoub, A., & Mehta, R. (2024) · Infectious Diseases and Therapy · doi:10.1007/s40121-024-01050-w · Cited by 8
Self-citation
Clinical Benefits of Sustained Oral Nirmatrelvir/Ritonavir Use for the Outpatient Treatment of COVID-19: Findings from the Taiwanese Health Authority Perspective Using a Decision Tree Modeling Approach
Sussman, M., Benner, J., Mugwagwa, T., Lee, J., Hung, S.-T., Yang, Y.-M., & Chen, Y. (2024) · Journal of Market Access & Health Policy · doi:10.3390/jmahp12040026 · Cited by 8
Biocompatible Iron Oxide Nanoparticles Display Antiviral Activity Against Two Different Respiratory Viruses in Mice
DeDiego, M. L., Portilla, Y., Daviu, N., López-García, D., Villamayor, L., Vázquez-Utrilla, P., Mulens‐Arias, V., Pérez-Yagüe, S., Nogales, A., Ovejero, J. G., et al. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s475323 · Cited by 8
Transformative approaches in SARS-CoV-2 management: Vaccines, therapeutics and future direction
Saha, A., Choudhary, S., Walia, P., Kumar, P., & Tomar, S. (2025) · Virology · doi:10.1016/j.virol.2025.110394 · Cited by 8
Willingness to pay for the effect of SARS-CoV-2 antivirals in preventing COVID-19 transmission to others in the Japanese population
Igarashi, A., Kurazono, K., Itsumura, N., Takeshima, T., & Iwasaki, K. (2025) · Journal of Medical Economics · doi:10.1080/13696998.2025.2461897 · Cited by 8
Antiviral efficacy of oral ensitrelvir versus oral ritonavir-boosted nirmatrelvir in COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial
Schilling, W. H., Jittamala, P., Wongnak, P., Watson, J. A., Boyd, S., Luvira, V., Siripoon, T., Ngamprasertchai, T., Batty, E. M., Beer, E., et al. (2025) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(25)00482-7 · Cited by 8
Design, Synthesis and Computational Insights of 7-Hydroxystilbene-Coumarin Hybrid Scaffolds as SARS-CoV-2 3CLpro Inhibitors
Khamto, N., Pruksaphon, K., Akkravijitkul, N., Choommongkol, V., Patnin, S., & Meepowpan, P. (2026) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2026.145240 · Cited by 8
A Versatile Class of 1,4,4-Trisubstituted Piperidines Block Coronavirus Replication In Vitro
de Castro, S., Stevaert, A., Maldonado, M., Delpal, A., Vandeput, J., Loy, B. V., Eydoux, C., Guillemot, J., Decroly, É., Gago, F., et al. (2022) · Pharmaceuticals · doi:10.3390/ph15081021 · Cited by 8
VV116 as a potential treatment for COVID-19
McCarthy, M. W. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2193668 · Cited by 8
Immunosuppressants exert differential effects on pan‐coronavirus infection and distinct combinatory antiviral activity with molnupiravir and nirmatrelvir
Wang, Y., Li, P., Lavrijsen, M., Rottier, R. J., den Hoed, C. M., Bruno, M. J., Kamar, N., Peppelenbosch, M. P., de Vries, A. C., & Pan, Q. (2023) · United European Gastroenterology Journal · doi:10.1002/ueg2.12417 · Cited by 8
Three to four mRNA COVID‐19 vaccines in multiple sclerosis patients on immunosuppressive drugs: Seroconversion and variant neutralization
Louapre, C., Belin, L., Marot, S., Hippolyte, A., Januel, É., Ibrahim, M., Jeantin, L., Zafilaza, K., Malet, I., Charbonnier‐Beaupel, F., et al. (2023) · European Journal of Neurology · doi:10.1111/ene.15925 · Cited by 8
Interactions of the Anti-SARS-CoV-2 Agents Molnupiravir and Nirmatrelvir/Paxlovid with Human Drug Transporters
Bakos, É., Temesszentandrási‐Ambrus, C., Özvegy‐Laczka, C., Gáborik, Z., Sarkadi, B., & Telbisz, Á. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411237 · Cited by 8
Risk of acute liver injury following the nirmatrelvir/ritonavir use
Wong, C. K. H., Mak, L., Au, I. C. H., Cheng, W. Y., So, C. H., Lau, K. T. K., Lau, E. H. Y., Cowling, B. J., Leung, G. M., & Yuen, M. (2023) · Liver International · doi:10.1111/liv.15673 · Cited by 8
Proxalutamide reduces SARS-CoV-2 infection and associated inflammatory response
Qiao, Y., Wotring, J. W., Zheng, Y., Zhang, C. J., Zhang, Y., Jiang, X., Pretto, C. D., Eyunni, S., Parolia, A., He, T., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2221809120 · Cited by 8
Pooling Different Placebos as a Control Group in a Randomized Platform Trial: Benefits and Challenges From Experience in the ACTIV-2 COVID-19 Trial
Moser, C., Chew, K. W., Ritz, J., Newell, M., Javan, A. C., Eron, J. J., Daar, E. S., Wohl, D. A., Currier, J. S., Smith, D. M., et al. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad209 · Cited by 8
Comparison between available early antiviral treatments in outpatients with SARS-CoV-2 infection: a real-life study
Rinaldi, M., Campoli, C., Gallo, M., Marzolla, D., Zuppiroli, A., Riccardi, R., Casarini, M., Riccucci, D., Malosso, M., Bonazzetti, C., et al. (2023) · BMC Infectious Diseases · doi:10.1186/s12879-023-08538-9 · Cited by 8
The prevention and treatment of COVID-19 in patients treated with hemodialysis
Zeng, B., Zhou, J., Peng, D., Dong, C., & Qin, Q. (2023) · European journal of medical research · doi:10.1186/s40001-023-01389-9 · Cited by 8
ACTIV-6: Operationalizing a decentralized, outpatient randomized platform trial to evaluate efficacy of repurposed medicines for COVID-19
The Accelerating Covid-19 Therapeutic Interventions and Vaccines (ACTIV)-6 Study Group (2023) · Journal of Clinical and Translational Science · doi:10.1017/cts.2023.644 · Cited by 8
Novel stability indicating HPLC method for the quantification of Nirmatrelvir in bulk drugs
Ilayaraja, P., Manivannan, M., & PARTHIBAN, P. (2023) · Microchemical Journal · doi:10.1016/j.microc.2023.109707 · Cited by 8
Nosocomial COVID‐19 infection in the era of vaccination and antiviral therapy
McNeil, T., Zhang, F., Moffatt, S., Emeto, T. I., & Tucker, E. C. (2023) · Internal Medicine Journal · doi:10.1111/imj.16298 · Cited by 8
Real-World Effectiveness Study of Nirmatrelvir-Ritonavir or Molnupiravir in Hospitalized Unvaccinated Patients with Chronic Respiratory Diseases and Moderate COVID-19 at Presentation
Kwok, W. C., Tam, T. C. C., Ho, J., Lam, D. C. L., Ip, M., & Ho, P. (2024) · International Journal of COPD · doi:10.2147/copd.s440895 · Cited by 8
Systematic Studies on the Anti-SARS-CoV-2 Mechanisms of Tea Polyphenol-Related Natural Products
Li, C., Chao, T., Lai, C.-L., Lin, C.-C., Pan, M. Y.-C., Cheng, C.-L., Kuo, C., Wang, L. H.-C., Chang, S., & Liang, P. (2024) · ACS Omega · doi:10.1021/acsomega.4c02392 · Cited by 8
Paxlovid reduces the 28-day mortality of patients with COVID-19: a retrospective cohort study
Zong, K., Li, X., Luo, C. H., Luo, C., Liu, B., Chen, J., Wu, H., Liu, Z., Zhuang, R., & Guo, S. (2024) · BMC Infectious Diseases · doi:10.1186/s12879-024-09482-y · Cited by 8
Cardiovascular Drug Interactions with Nirmatrelvir/Ritonavir for COVID-19: Considerations for Daily Practice
Lenarda, A. D., Ferri, N., Lanzafame, M., Montuori, E. A., & Pacelli, L. (2024) · European Cardiology Review · doi:10.15420/ecr.2024.04 · Cited by 8
Association Between SARS-CoV-2 Viral Load and COVID-19 Vaccination in 4 Phase 3 Trials
Janes, H., Fisher, L. H., Kee, J. J., Parameswaran, L., Goepfert, P., Falsey, A. R., Ludwig, J., Magaret, C. A., Gilbert, P. B., Kublin, J. G., et al. (2024) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiae400 · Cited by 8
Rational Design of Macrocyclic Noncovalent Inhibitors of SARS-CoV-2 M pro from a DNA-Encoded Chemical Library Screening Hit That Demonstrate Potent Inhibition against Pan-Coronavirus Homologues and Nirmatrelvir-Resistant Variants
Wang, X., Gotchev, D., Fan, K. Y., Vega, M. M., Mani, N., McGovern-Gooch, K. R., Cuconati, A., Tercero, B., Wang, X., Carpino, P. A., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02009 · Cited by 8
Selective phosphodiesterase 4 inhibitor roflumilast reduces inflammation and lung injury in models of betacoronavirus infection in mice
Beltrami, V. A., Martins, F. R. B., Martins, D. G., Queiroz‐Junior, C. M., Félix, F. B., Resende, L. C., Santos, F. R. D. S., Lacerda, L. D. S. B., Costa, V. R. D. M., da Silva, W. N., et al. (2025) · Inflammation Research · doi:10.1007/s00011-024-01985-3 · Cited by 8
A tale of two drugs: Molnupiravir and Paxlovid
Waters, M. D., & Warren, S. G. (2025) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2025.108533 · Cited by 8
Multiple sclerosis and COVID-19: interactions and unresolved issues
Zabalza, A., Thompson, A. J., Rotstein, D., Bar‐Or, A., & Montalbán, X. (2025) · The Lancet Neurology · doi:10.1016/s1474-4422(25)00006-7 · Cited by 8
Acute pulmonary emboli following rebound phenomenon after Nirmatrelvir/Ritonavir treatment for COVID-19
Birabaharan, M., & Martin, T. (2022) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2022.08.012 · Cited by 8
Randomized Open Investigation Determining Steroid Dose in Severe COVID-19: The ROIDS-Dose Clinical Trial
Rabascall, C. X., Lou, B. X., Dhar, S., Hasan, Z., Fryman, C. J., Izard, S. M., Makaryus, M. R., Acharya, S., Mastroianni, F., Kämper, M., et al. (2022) · Cureus · doi:10.7759/cureus.31086 · Cited by 8
Early Treatment with Fluvoxamine among Patients with COVID-19: A Cost-Consequence Model
Mills, F. P., Reis, G., Wilson, L. A., Thorlund, K., Forrest, J. I., Guo, C. M., Boulware, D. R., Mills, E. J., & _, _. (2022) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.22-0106 · Cited by 8
Strategies Tackling Viral Replication and Inflammatory Pathways as Early Pharmacological Treatment for SARS-CoV-2 Infection: Any Potential Role for Ketoprofen Lysine Salt?
Mariniello, D. F., Allocca, V., D’Agnano, V., Villaro, R., Lanata, L., Bagnasco, M., Aronne, L., Bianco, A., & Perrotta, F. (2022) · Molecules · doi:10.3390/molecules27248919 · Cited by 9
Lung Transplantation for COVID-19 Pulmonary Sequelae
Kehara, H., Mangukia, C. V., Sunagawa, G., Iturra, S. A., Yanagida, R., Kashem, M. A., Persidsky, Y., Shenoy, K. V., Mamary, A. J., Marchetti, N. T., et al. (2022) · Transplantation · doi:10.1097/tp.0000000000004428 · Cited by 8
Nirmatrelvir‐ritonavir therapy and COVID‐19 vaccination improve clinical outcomes of SARS‐CoV‐2 Omicron variant infection
Qi, T., Jin, Y., Wang, H., Liao, Y., Liu, T., Mao, E., Li, F., Li, Y., Fan, X., & Ling, Y. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28497 · Cited by 8
The Impact and Treatment of COVID-19 in Hemodialysis Patients
Katagiri, D., & Kikuchi, K. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12030838 · Cited by 8
Cancer, more than a “COVID-19 co-morbidity”
Jani, C., Schooley, R. T., McKay, R. R., & Lippman, S. M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1107384 · Cited by 9
Efficacy of Sotrovimab (SOT), Molnupiravir (MOL), and Nirmatrelvir/Ritponavir (N/R) and Tolerability of Molnupiravir in Outpatients at High Risk for Severe COVID-19
Kauer, V., Totschnig, D., Waldenberger, F. R., Augustin, M., Karolyi, M., Naegeli, M., Wenisch, C., & Zoufaly, A. (2023) · Viruses · doi:10.3390/v15051181 · Cited by 8
Effect of therapeutic-dose heparin on severe acute kidney injury and death in noncritically ill patients hospitalized for COVID-19: a prespecified secondary analysis of the ACTIV4a and ATTACC randomized trial
Smilowitz, N. R., Hade, E. M., Kornblith, L. Z., Castellucci, L. A., Cushman, M., Farkouh, M. E., Gong, M. N., Heath, A., Hunt, B. J., Kim, K. S., et al. (2023) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2023.102167 · Cited by 8
Association Between Anterior Nasal and Plasma SARS-CoV-2 RNA Levels and Hospitalization or Death in Nonhospitalized Adults With Mild-to-Moderate COVID-19
Giganti, M. J., Chew, K. W., Eron, J. J., Li, J. Z., Pinilla, M., Moser, C., Javan, A. C., Fischer, W. A., Klekotka, P. A., Margolis, D. M., et al. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad287 · Cited by 8
Selective, broad-spectrum antiviral photodynamic disinfection with dicationic imidazolyl chlorin photosensitizers
Arnaut, Z. A., Pinto, S. M. A., Aroso, R. T., Amorim, A. S., Lobo, C. S., Scháberle, F. A., Pereira, D., Núñez, J. G., Nunes, S. C. C., Pais, A. A. C. C., et al. (2023) · Photochemical & Photobiological Sciences · doi:10.1007/s43630-023-00476-4 · Cited by 10
Clinical outcomes of nirmatrelvir-ritonavir use in pregnant women during the Omicron wave of the coronavirus disease 2019 pandemic
Lin, C.-W., Liang, Y., Chuang, M., Tseng, C.-H., Tsai, P., & Su, M. (2023) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2023.10.007 · Cited by 8
A retrospective cohort study of prescribing outcomes in outpatients treated with nirmatrelvir–Ritonavir for COVID-19 in an interdisciplinary community clinic
Leung, V., Gill, S., Llanes, A., Khawaja, A., Stagg, A., McCready, J., Jacubovich, M., Ho, G., Powis, J. E., & Kandel, C. E. (2023) · PLoS ONE · doi:10.1371/journal.pone.0293302 · Cited by 8
Real-world use of nirmatrelvir-ritonavir in COVID-19 outpatients during BQ.1, BQ.1.1., and XBB.1.5 predominant omicron variants in three U.S. health systems: a retrospective cohort study
Aggarwal, N. R., Beaty, L. E., Bennett, T. D., Fish, L. E., Jacobs, J. R., Mayer, D. A., Molina, K. C., Peers, J. L., Richardson, D. B., Russell, S., et al. (2024) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2024.100693 · Cited by 8
Effect of Opaganib on Supplemental Oxygen and Mortality in Patients with Severe SARS-CoV-2 Based upon FIO2 Requirements
Neuenschwander, F. C., Barnett‐Griness, O., Piconi, S., Maor‬‏, ‪., Sprinz, E., Assy, N., Khmelnitskiy, O., Lomakin, N. V., Goloshchekin, B. M., Nahorecka, E., et al. (2024) · Microorganisms · doi:10.3390/microorganisms12091767 · Cited by 8
Validating a Proteomic Signature of Severe COVID-19
Cosgriff, C. V., Miano, T. A., Mathew, D., Huang, A. C. C., Giannini, H. M., Kuri-Cervantes, L., Pampena, M. B., Ittner, C. A. G., Weisman, A. R., Agyekum, R. S., et al. (2022) · Critical Care Explorations · doi:10.1097/cce.0000000000000800 · Cited by 8
The Potential of Intentional Drug Development
Rubin, E. J., & Baden, L. R. (2022) · New England Journal of Medicine · doi:10.1056/nejme2202160 · Cited by 8
Fluvoxamine for Outpatient Treatment of COVID-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical TrialPreprint
McCarthy, M. W., Naggie, S., Boulware, D. R., Lindsell, C. J., Stewart, T. G., Felker, G. M., Jayaweera, D. T., Sulkowski, M., Gentile, N., Bramante, C. T., et al. (2022) · medRxiv · doi:10.1101/2022.10.17.22281178 · Cited by 8
Drug-induced Liver Injury With Ritonavir-Boosted Nirmatrelvir: Evidence From Coronavirus Disease 2019 Emergency Use Authorization Adverse Event Reporting System
Li, G., & Yu, G. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.02.008 · Cited by 8
Pervasive aggregation and depletion of host and viral proteins in response to cysteine-reactive electrophilic compoundsPreprint
Julio, A. R., Shikwana, F., Truong, C. C., Burton, N. R., Dominguez, E. R., Turmon, A. C., Cao, J. X., & Backus, K. M. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.30.564067 · Cited by 8
Rebound of COVID-19 With Nirmatrelvir–Ritonavir Antiviral Therapy
Cohen, M. S., & Brown, E. R. (2023) · Annals of Internal Medicine · doi:10.7326/m23-2887 · Cited by 8

Authors: Hammond, J., Leister-Tebbe, H., Gardner, A., Abreu, P., Bao, W., Wisemandle, W., Baniecki, M., Hendrick, V. M., Damle, B., Simón-Campos, A., Pypstra, R., & Rusnak, J. M.
Affiliations: Pfizer (United States) (US)
From Global Product Development, Pfizer, Collegeville, PA (J.H., H.L.-T.); Global Product Development (A.G.) and Early Clinical Development (M.L.B.), Pfizer, Cambridge, MA; Global Product Development, Pfizer, New York (P.A., W.B., B.D., R.P.); Global Product Development, Pfizer, Lake Forest, IL (W.W.); Medical and Safety, Pfizer, Sandwich, United Kingdom (V.M.H.); Köhler and Milstein Research, Mérida, Yucatan, Mexico (A.S.-C.); and Global Product Development, Pfizer, Tampa, FL (J.M.R.).
Corresponding author: Hammond, Jennifer
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2022-04-14
Volume: 386
Issue: 15
Pages: 1397-1408
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa2118542
PMC: PMC8908851
OpenAlex: W4212904481
Cited by: 2,323
References: 21
Citations by year: 2026: 186 · 2025: 319 · 2024: 517 · 2023: 769 · 2022: 525
FWCI: 261.43
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.nejmgroup.org/legal/terms-of-use.htm (vor)
Locations: New England Journal of Medicine (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Pfizer
Topics: Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Health Sciences › Medicine › Epidemiology › Respiratory viral infections research
Keywords: nirmatrelvir, COVID-19 pandemic, SARS-CoV-2, Mpro inhibitors, ritonavir, oral antiviral therapy, high-risk adults, non-hospitalized patients, viral load, unvaccinated patients, early treatment, SARS-CoV-2 variants, Omicron variant
MeSH terms: Viral Protease Inhibitors, COVID-19, SARS-CoV-2, COVID-19 Drug Treatment, Administration, Oral, Adult, Antiviral Agents, Double-Blind Method, Drug Combinations, Hospitalization, Humans, Lactams, Leucine, Nitriles, Proline, Vaccination, Treatment Outcome, Disease Progression, Ritonavir, Viral Load

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks